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AbstrACt
Objectives A significant proportion of cardiovascular 
disease (CVD) cannot be explained by well-known risk 
factors such as high cholesterol, hypertension and 
diabetes. One potential novel risk factor for CVD is asthma. 
We aimed to investigate the association between asthma 
and mortality due to CVD.
Design Prospective cohort study.
setting A large health check-up programme from 1994 to 
2011 in Taipei, Taiwan.
Participants 446 346 Taiwanese adults. Each participant 
answered questions regarding asthma history (yes/no) 
and current daily use of asthma medications (yes/no). 
Active asthma was defined as those using current daily 
medications for asthma.
Outcomes The participants were followed for mortality 
from CVD, coronary heart disease (CHD) and stroke 
obtained through linkage to the cause-of-death register 
until 31 December 2011.
results We found an increased risk of dying from CVD in 
individuals with active asthma (adjusted HR (aHR) 1.32, 
95% CI 1.08 to 1.62). The risk of death from CHD or stroke 
was increased in a similar manner (aHR 1.16, 95% CI 0.78 
to 1.73 and aHR 1.23, 95% CI 0.86 to 1.74, respectively) 
although the HR estimates were less precise than that 
of CVD. For deaths from CVD, CHD and stroke, we found 
stronger associations with active asthma than non-active 
asthma, and for CVD and stroke stronger associations in 
men than women.
Conclusion Our study suggests that asthma, particularly 
active asthma, may be associated with adverse 
cardiovascular consequences.
IntrODuCtIOn 
An estimated 17 million people die of cardio-
vascular diseases (CVDs) every year.1 Among 
the main forms of CVD are coronary heart 
disease (CHD) and stroke.1 Some well-known 
factors that increase the risk of developing 
CVD are unfavourable cholesterol levels, 
high blood pressure, diabetes and cigarette 
smoking. A significant proportion of CVD 
cannot be explained by these known risk 
factors, and a high incidence of the diseases 
makes it important to detect other potentially 
modifiable risk factors. One novel potential 
risk factor is asthma. As much as 330 million 
adults worldwide are estimated to have 
asthma,2 emphasising the potential public 
health importance of any effect of asthma on 
the occurrence of CVD. Such an association 
is plausible as it is suggested that asthma is 
associated with low-grade systemic inflam-
mation and decline in pulmonary function3 
which has been linked to an increased risk of 
CVD later in life.4 5 Despite the plausibility of 
such an association, only a few studies have 
investigated the association between asthma 
and risk of CVD.5 6 For example, Iribarren et 
al6 recently reported an HR of 1.22 (95% CI 
1.14 to 1.31) for CHD-related death or hospi-
talisation in women with asthma compared 
with women without asthma after adjusting 
for demographic and established CHD risk 
factors; there was no association in men. To 
strengthen the existing evidence for a caus-
ative association, there is a need for large 
prospective studies on asthma and the risk of 
CVD, which can additionally investigate the 
influence of sex.
Approximately, 5.5 million people die 
from stroke every year.1 Among the survi-
vors, the consequences on physical, cognitive 
strengths and limitations of this study
 ► We had objective measures of lung function that 
allowed us to exclude possible misclassification of 
asthma with chronic obstructive pulmonary disease.
 ► However, there is no gold standard for asthma di-
agnosis, and asthma was confirmed based on 
self-report.
 ► Taiwan has some of the lowest mortality rates from 
cardiovascular disease (CVD) in the world; our sam-
ple was relatively young and this led to a relatively 
small number of CVD deaths.
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and emotional functioning are potentially devastating. 
Despite the serious consequences of stroke, asthma as a 
novel risk factor has not been thoroughly investigated.5 7 
Our aim was to examine whether asthma at baseline was 
associated with an increased risk of deaths from CVD, and 
more specifically, CHD and stroke using a large cohort 
of more than 400 000 Taiwanese adults participating in a 
health check-up programme.
MethODs
study population
The study cohort consisted of 593 225 Taiwanese adults 
aged 20 years or older who participated in a large 
health check-up programme from 1994 to 2011, run 
by MJ Health Management Institution, Taipei, Taiwan 
(https://www. mjclinic. com. tw). The baseline question-
naire included questions about history of asthma and 
current use of asthma medications. The participants 
went through a number of biochemical tests and phys-
ical examinations as described previously.8 In the present 
study, 67 682 (11.4%) of 593 225 adults were excluded 
due to missing information on asthma or asthma medi-
cations, and a further 79 197 (13.4%) were excluded as 
information was missing on potential confounding vari-
ables including sociodemographic and life style factors. 
The analysis included 446 346 (75%) participants who 
attended check-ups between 1998 and 2011 and who 
had full information on asthma, asthma medications and 
potential confounding variables.
Asthma
Participants answered questions related to asthma history 
(yes/no) and current daily use of asthma medications 
(yes/no). We first defined asthma as those reporting a 
history of asthma or current daily use of asthma drugs, 
and then grouped these individuals into two subgroups: 
(1) non-active asthma (those who only reported a history 
of asthma but not current use of asthma medications) and 
(2) active asthma (those who reported current daily use of 
asthma medications). Self-reported asthma is commonly 
used in population-based studies; this approach has been 
evaluated and displays reasonable sensitivity and speci-
ficity.9 10
CVD mortality
From baseline, the participants were followed for 
mortality until the end of follow-up, 31 December 2011, 
through linkage to the Taiwanese cause-of-death register 
using the national identification numbers. The Interna-
tional Classification of Diseases, 9th Revision (ICD-9) 
or 10th Revision (ICD-10) codes were used to identify 
mortality from CVD (ICD-9 390–459; ICD-10 I00–I99), 
CHD (ICD-9 codes 410–414; ICD-10 I20–I25) and stroke 
(ICD-9 430–438; ICD-10 I60–I69). A previous study 
showed good accuracy of cause-of-death coding for both 
heart diseases and stroke in Taiwan.11
Covariates
At the baseline health check-up, participants were wearing 
light-weight clothes and were measured barefoot. Their 
weight (to the nearest 0.1 kg) and height (to the nearest 
mm) were measured using an auto-anthropometer, 
Nakamura KN-5000A (Nakamura, Tokyo, Japan) and their 
body mass index (BMI) was calculated (kg/m2). After 5 min 
seated rest, blood pressure was measured two times, at 
10 min intervals, using a computerised auto-mercury sphyg-
momanometer (CH-5000, Citizen, Tokyo, Japan). We used 
the mean of the two measurements in our analysis. Glucose, 
total cholesterol and triglyceride levels were measured in 
blood collected after overnight fasting using the Hitachi 
7150 auto-analyser (Hitachi, Tokyo, Japan). Respiratory 
functions were measured using an electronic spirometer 
(HI-501, HI-701 or HI-801; Chest M.I., Tokyo, Japan).
The participants reported their education (middle 
school or below, high school, junior college, college or 
higher), marital status (single, married, divorced or sepa-
rated, widowed), smoking status (never, former, current), 
alcohol consumption (no or occasional use, former 
drinking, regular drinking) and physical activity (inac-
tive, low, moderate or high). They also reported whether 
they had a history of hypertension, diabetes, heart 
disease, heart surgery, stroke or whether they were taking 
medications for hypertension, diabetes or heart diseases. 
Hypertension was defined as the presence of any of the 
following: reporting a history of hypertension, taking any 
hypertensive drugs, a systemic blood pressure ≥140 mm 
Hg or a diastolic blood pressure ≥90 mm Hg. Diabetes was 
defined as the presence of any of the following: reporting 
a history of diabetes, taking diabetes medications or a 
fasting blood sugar ≥126 mmol/L.
statistical methods
We used Cox proportional hazards models to investigate 
the associations of self-reported asthma with CVD, CHD 
and stroke mortality, respectively. Time at entry was date 
of recruitment and time of exit was 31 December 2011, or 
death if earlier.
We estimated the association between asthma (those 
answering ‘yes’ to asthma history or use of asthma medica-
tions), and CVD, CHD and stroke mortality adjusting for 
age and sex (model 1). In a second model, we adjusted 
for age, sex, education and marital status, smoking status, 
alcohol consumption, physical activity, hypertension, 
diabetes, BMI, total cholesterol, triglycerides, history 
of heart disease/heart surgery/use of heart drugs, and 
history of stroke (model 2). We also investigated the asso-
ciations between active and non-active asthma and CVD, 
CHD and stroke mortality.
We investigated whether the associations differed in men 
and women, between age groups (above and below 60 years) 
and by smoking status (non-current smoker vs current 
smokers) by including interaction terms in the models and 
conducting subgroup analyses. We reported the p value 
for interaction by comparing models with and without the 
interaction terms using a likelihood ratio test.
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We conducted a series of sensitivity analyses to test the 
robustness of our findings. First, we excluded deaths due 
to CVD, CHD or stroke occurring in the first 2 years of 
follow-up, as these deaths may be due to pre-existing CVD 
and not asthma. We excluded participants with a history 
of heart disease, heart surgery, use of heart medications 
and a history of stroke at baseline in a second sensitivity 
analysis. Lastly, we excluded participants with possible 
chronic obstructive pulmonary disease (COPD) at base-
line. In this analysis, we excluded those who had an FEV1/
FVC ratio (forced expiratory volume in 1 s divided by 
forced vital capacity) <0.7.
The proportional hazards assumption was examined by 
plotting Schoenfeld residuals with time and by examining 
their correlation.
Our study complies with the Declaration of Helsinki.
Patient and public involvement
This study used data from the MJ Health Management 
Institution, Taipei, Taiwan and patients were not involved 
in the design, recruitment or conduct of this study. The 
outcome measures were not informed by patients’ priori-
ties, experience and preferences. The MJ Health Manage-
ment Institution will disseminate all key findings from 
this study on its website. Participants were thanked in the 
acknowledgement section.
results
Among the 446 346 participants, there were 2945 deaths 
from CVD, 780 deaths from CHD and 1146 deaths from 
stroke over the follow-up period. At baseline, 3.34% 
(n=14 917) of the participants reported to have asthma; 
2.60% (n=11 603) reported to have a history of asthma 
and 0.74% (n=3314) reported to have active asthma. The 
characteristics of the participants according to baseline 
asthma status are presented in table 1.
In the age and sex-adjusted model (model 1), those 
with asthma had a 27% (HR 1.27, 95% CI 1.09 to 1.48) 
increased risk of CVD (table 2). In the multiadjusted 
model (model 2), the association attenuated (HR 1.13, 
95% CI 0.97 to 1.31). Using a stricter definition of asthma 
(active asthma), we found that those that reported any 
current use of asthma medications had a 32% (HR 1.32, 
95% CI 1.08 to 1.62) increased risk of dying from CVD in 
model 2. In contrast, there was no association between 
non-active asthma and CVD mortality (HR 0.96, 95% CI 
0.77 to 1.62).
There was evidence that the association between 
asthma (grouped as non-active and active asthma) and 
CVD was stronger in men than in women (p for inter-
action=0.005 in model 2) (table 3). Men who reported 
asthma had a 25% increased risk (HR 1.25, 95% CI 
1.04 to 1.49) of dying from CVD in model 2, those with 
active asthma had a 63% increased risk (HR 1.63, 95% CI 
1.30 to 2.04) compared with men without asthma, while 
men with non-active asthma showed no increased risk 
(HR 0.90, 95% CI 0.68 to 1.19). No associations were 
found in women. When stratifying by age, we found 
no appreciable differences (online supplementary 
table 1).
Table 1 Characteristics of the Participants in the MJ Health Check-up Programme, Taiwan (n=446 346)
Characteristic
Asthma 
(N=14 917)
No asthma 
(N=43 1429)
n (%) n (%)
Female 6893 (46.2) 220 253 (51.1)
College or higher education 5726 (38.4) 143 649 (33.3)
Married 8659 (58.0) 281 011 (65.1)
Current smoker 3461 (23.2) 98 730 (22.9)
Regular alcohol use 1210 (8.1) 29 884 (6.9)
Physically inactive 7462 (50.0) 220 976 (51.2)
Hypertension (history of hypertension+hypertensive drug 
use+systolic blood pressure  ≥140 mm Hg or diastolic blood pressure  
≥90 mm Hg)
3121 (20.9) 77 972 (18.1)
Diabetes (history of diabetes+diabetes drug use+fasting blood glucose ≥126) 
mmol/L)
841 (5.6) 21 274 (4.9)
History of heart disease/heart surgery/use of heart drugs 1045 (7.0) 15 044 (3.5)
History of stroke 129 (0.9) 2050 (0.5)
Mean (SD) Mean (SD)
Age (years) 41.0 (15.6) 40.0 (13.4)
Body mass index (kg/m2) 23.4 (3.8) 23.0 (3.6)
Total cholesterol (mmol/L) 5.0 (1.0) 5.0 (1.0)
Triglycerides (mmol/L) 3.0 (2.4) 3.0 (2.6)
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The associations between asthma and CHD mortality 
were consistent with those of CVD mortality, although less 
precise due to the smaller number of deaths (table 2). 
When stratifying by sex, we found a 67% increased risk 
(HR 1.67, 95% CI 1.08 to 2.59) for CHD among men with 
active asthma in the age-adjusted model (model 1), but 
the association was largely attenuated when adjusting for 
additional potential confounders (model 2). We did not 
find any association among women (table 3). We found 
more than double the risk in those below 60 years (HR 
2.57, 95% CI 1.06 to 6.26) in model 1, but the CI was wide 
and the association was attenuated when adjusting for 
additional potential confounders (online supplementary 
table 1).
When investigating mortality due to stroke, we found 
similar but slightly weaker associations between asthma 
and stroke mortality than between asthma and CVD 
mortality (table 2). We found a 77% increased risk in 
men with active asthma (HR 1.77, 95% CI 1.22 to 2.57) 
in model 1, that persisted after adjusting for potential 
confounders in model 2 (HR 1.62, 95% CI 1.11 to  2.35) 
(table 3). This increase was not seen in women (p for 
interaction=0.032). We found no differences in the asso-
ciation between asthma and stroke mortality between age 
groups (ie, below and above 60 years) (online supple-
mentary table 1).
When excluding deaths occurring during the two first 
years of follow-up, the results did not change considerably 
for any of the cardiovascular outcomes (online supple-
mentary table 2). When excluding participants with a 
history of heart disease, heart surgery, use of heart medi-
cations and a history of stroke at baseline, the results were 
generally similar to those of the main analysis except that 
the association between asthma and CHD was largely 
attenuated, although the number of CHD deaths was 
small (n=13 and 10 in the non-active and active asthma 
groups, respectively) in this analysis (online supplemen-
tary table 3). When excluding individuals with FEV1/FVC 
ratio <0.7 at baseline, the analysis based on the remaining 
sample showed that the effect estimate remained the 
same although the CI widened slightly because of lower 
power in this analysis (online supplementary table 4).
Overall, there was no statistical evidence for a differ-
ence in the association between asthma and CVD/CHD/
stroke mortality between current smokers and non-cur-
rent smokers (all p for interaction >0.05), although 
there was a tendency towards stronger associations in 
current smokers than in non-smokers or ex-smokers 
(online supplementary table 5).
DIsCussIOn
To the best of our knowledge, this is the largest study to 
date on asthma and CVD mortality. In this sample of more 
than 400 000 Taiwanese adults, we found an increased 
risk of dying from CVD in individuals with active, but not 
non-active, asthma. The risk of death from CHD or stroke 
was increased in a similar manner, however, in sensitivity T
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analysis excluding those with previous heart disease, only 
the associations with CVD and stroke mortality remained. 
For deaths from CVD and stroke, we found stronger asso-
ciations with active asthma in men than in women.
A few previous studies have investigated the association 
between asthma and risk of CVD. One very large recent 
study including almost one million Italian adults agreed 
with our findings and reported asthma to be moderately 
associated with different CVDs.12 Additionally, this study 
did not find any differences in the association between 
men and women, while our study observed a stronger 
association in men. This Italian study was cross-sectional, 
however, and there is no way of knowing whether the 
CVD diagnosis preceded the asthma diagnosis. Addition-
ally, this study did not have access to spirometry measure-
ments such as FEV1 and FVC and thus was not able to 
exclude those with a FEV1/FVC ratio of less than 0.7 to 
minimise the possibility of misclassification between 
asthma and COPD.
A smaller study was undertaken in Australia including 
approximately 4000 people among whom 500 were clas-
sified as having asthma.13 Individuals with asthma were 
identified by self-report, and through identification of 
significant reversibility of airway obstruction. The results 
were in accordance with our findings and when subjects 
with COPD were excluded from the analysis (FEV1/
FVC <0.7 and FEV1 <80% of predicted), the association 
between asthma and CVD remained.
CHD contributes to a large part of the burden of CVD14 
and the risk of complications or even death is high, thus 
detecting novel risk factors is essential. A few studies 
have found an increased risk of CHD in patients with 
asthma.15 16 However, the results are inconsistent, and a 
recent study including almost 16 000 participants from 
the Atherosclerosis Risk in Communities (ARIC) Study 
failed to confirm this increase in risk of CHD in patients 
with current asthma (HR 0.69, 95% CI 0.46 to 1.05).5
In the current study, we generally observed stronger 
results in men than in women in this adult Taiwanese 
population. By contrast, other studies have previously 
found stronger associations in women than men. A 
large prospective study by Iribarren et al17 found that 
the increased risk of CHD was higher in women with 
asthma (HR 1.49, 95% CI 1.43 to 1.56) than in men (HR 
1.28, 95% CI 1.21 to 1.34) (p for interaction <0.001). 
The authors speculate that the increased risk of CHD 
among people with asthma may be due to chronic inflam-
mation in people with asthma. Supporting this is the 
fact that women with asthma tend to have more severe 
disease than men with asthma,18 and likely more systemic 
inflammation.
In spite of the devastating consequences of stroke, 
asthma as a novel risk factor has not been thoroughly 
investigated and only a few studies have examined this 
association. The previously mentioned study using data 
from the ARIC Study,5 found similar results to ours, 
with a 55% increased risk of stroke (HR 1.55, 95% CI 
0.95 to 2.52) in patients with current asthma compared 
with those without asthma. A recent meta-analysis of 
five studies on asthma and stroke found a pooled HR of 
1.32 (95% CI 1.13 to 1.54).19 In contrast to our findings, 
this meta-analysis found that the associations between 
asthma and stroke were stronger in women (HR 1.42, 
95% CI 1.15 to 1.76) than in men (HR 1.19, 95% CI 
0.90 to 1.43). The authors speculate that sex hormones 
could play a crucial role in modulating immunological 
inflammation in asthma. However, our results showed 
an increased risk in men, but not in women. The under-
lying reasons driving these differences between studies 
are not clear and further investigations from countries 
with different ethnicities may help to shed light on this 
observation.
The biological mechanisms by which asthma may 
influence CVD are not known, but several mecha-
nisms have been suggested. Asthma is associated with 
low-grade systemic inflammation,20 which could influ-
ence later risk of CVD.21 Previous studies also suggest 
that C-reactive protein is associated with both asthma22 
and CVD.23 24 Lung function impairment is also associ-
ated with CVD risk.25 26 Patients with impaired lung func-
tion have increased inflammatory markers (including 
C-reactive protein, interleukin-1β and interleukin-6),27 
which are associated with atherosclerosis and cardiovas-
cular events.21 28 Long-term airway remodelling from 
the inflammatory response in asthma can produce irre-
versible airway obstruction and cause a decline in lung 
function.29 In addition, severe asthma exacerbations are 
associated with a more rapid decline in lung function.30 
Another hypothesis is that asthma is associated with risk 
of CVD through asthma medication use, in particular 
the cardiotoxic effects of beta-2 (β2) agonists.31 32 Finally, 
asthma may be associated with CVD due to other factors 
such as obesity,33 smoking34 or physical inactivity.35 It is 
also possible that the association between asthma and 
CVD is due to comorbidities such as diabetes which 
has a strong link to CVD36 and also to asthma.37 In our 
study, we adjusted for these potential confounders and 
it is unlikely that confounding by these factors would be 
behind the observed associations.
To the best of our knowledge, our study is the largest 
to date, investigating the association between asthma and 
risk of death from CVD. Despite the large study size, the 
objective measures of lung function that allowed us to 
exclude possible misclassification of asthma with COPD, 
and the wide range of potential confounders included 
in our models, the limitations of this study must be 
considered.
There is no gold standard for asthma diagnosis and 
despite using spirometry measures to exclude possible 
COPD, asthma in this study was indicated by self-report. 
Additionally, we cannot rule out the potential misdiag-
nosis of heart disease as asthma. Among those diagnosed 
with asthma, we were unable to separate patients with 
asthma by disease onset (ie, childhood vs adulthood) or 
any other phenotype such as obesity-related, exercise-in-
duced and neutrophilic asthma,38 and it is possible that 
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these phenotypes differ in regard to asthma triggers,39 
gender distribution39 and systemic inflammation.40 For 
example, obesity-related asthma which usually develops 
in adulthood might be of particular importance to the 
development of CVD. However, since we were unable to 
differentiate between these subgroups our observations 
may not be representative of each. Finally, patients who 
used asthma medications less frequently than daily were 
grouped together with other patients with only a history 
of asthma, defining a very heterogeneous group which 
might be a limitation of this study.
Taiwan and some other East Asian countries such as 
Japan and Hong Kong have some of the lowest mortality 
rates from CVD in the world.41 42 Furthermore, our sample 
was fairly young (mean age 40.4 years), and these may 
have contributed to the relatively small number of CVD 
deaths in our study. This may have reduced our power to 
detect any small effects of asthma on risk of CVD death.
Observational studies inherently limit causal infer-
ence. Although we adjusted for a number of potential 
confounders in our analyses, there is a possibility of 
uncontrolled confounding contributing to the observed 
associations. Specifically, we did not have information on 
pack-years of cigarette smoking which could be a poten-
tial confounder. However, any residual confounding 
would need to be strongly associated with both asthma 
and CVD mortality and be unrelated to the covariates 
included in our models. Additionally, bias due to the 
exclusion of participants with missing information might 
have limited our study.
Finally, the sample was from a health check-up 
programme run by a private company and the partici-
pants may have come from a somewhat more advantaged 
socioeconomic position and therefore our findings may 
not be representative of the general population. However, 
the cohort was similar to the general population reported 
in a national survey43 in terms of certain characteristics 
including the prevalence of smoking.
COnClusIOn
Our study suggests that asthma, particularly active asthma, 
may be associated with adverse cardiovascular conse-
quences. For deaths from CVD and stroke, the associa-
tion was stronger in men than in women. The associations 
persisted even after adjustment for established CVD risk 
factors. Further studies are needed to better elucidate the 
mechanisms underlying this association and to clarify any 
sex differences in the association.
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